|
WO2010052222A1
|
|
(dihydro)naphthyridinone derivatives as histamine h3 receptor antagonists
|
|
WO2010026113A1
|
|
Acyl- and sufonyl tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
|
|
WO2010020556A1
|
|
New bradykinin b1 antagonists
|
|
US2011053951A1
|
|
Methods for treating disorders using nmda nr2b-subtype selective antagonist
|
|
WO2009095394A1
|
|
Diazepanes as histamine h3 receptor antagonists
|
|
EP2161266A1
|
|
Benzofuran derivatives as orexin receptor antagonists
|
|
WO2009024324A2
|
|
Treatment of sleep disorders
|
|
CA2696703A1
|
|
Treatment of sleep disorders
|
|
EP2155678A1
|
|
New bradykinin b1 antagonists
|
|
EP2053397A1
|
|
PPM1E proteins and nucleic acids as targets for neurodegenerative diseases
|
|
EP1891241A2
|
|
Diagnostic and therapeutic target adarb2 proteins for neurodegenerative diseases
|
|
US2009047274A1
|
|
Diagnostic and therapeutic target cdc2l6 proteins for neurodegenerative diseases
|
|
WO2006128906A1
|
|
Diagnostic and therapeutic target slc39a11 proteins for neurodegenerative diseases
|
|
US2009133135A1
|
|
Diagnostic and Therapeutic Target SLC39A11 Proteins for Neurodegenerative Diseases
|
|
EP1888783A2
|
|
Kcnn3 as diagnostic and therapeutic target for alzheimer's disease
|
|
WO2006015976A1
|
|
Diagnostic and therapeutic use of a plasma membrane atpase
|
|
EP1771578A2
|
|
Diagnostic and therapeutic use of slim3 for neurodegenerative diseases
|
|
EP1745296A2
|
|
Diagnostic and therapeutic use of kcnj6 for alzheimer's disease
|
|
EP1735626A2
|
|
Diagnostic and therapeutic use of kcnc1 for neurodegenerative diseases
|
|
US2008051334A1
|
|
Diagnostic and Therapeutic Use of Kcnc1 for Neurodegenerative Diseases
|
